Shopping Cart
Remove All
Your shopping cart is currently empty
Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $1,980 | In Stock | In Stock | |
| 5 mg | $4,160 | - | In Stock | |
| 10 mg | $5,620 | - | In Stock | |
| 25 mg | $8,360 | - | In Stock | |
| 50 mg | $11,200 | - | In Stock | |
| 100 mg | $15,200 | - | In Stock |
| Description | Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A. |
| In vivo | Emicizumab (1.5-10 mg/kg; i.v.; 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia type A bleeding model with an FVIII equivalent of 9 U/dL.[1]
Emicizumab (3 mg/kg; intravenously) provides additional hemostatic activity when combined with low-dose FVIII (10 U/dL).[1] |
| Synonyms | RO 5534262, ACE 910 |
| Molecular Weight | 145.14 kDa |
| Cas No. | 1610943-06-0 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.